

# Naru Kondo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7120528/publications.pdf>

Version: 2024-02-01

69  
papers

1,426  
citations

430874

18  
h-index

345221

36  
g-index

69  
all docs

69  
docs citations

69  
times ranked

2294  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Factors After Surgical Resection for Intrahepatic, Hilar, and Distal Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2011, 18, 651-658.	1.5	210
2	Prognostic Impact of Perioperative Serum CA 19-9 Levels in Patients with Resectable Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2010, 17, 2321-2329.	1.5	146
3	Number of Metastatic Lymph Nodes, but Not Lymph Node Ratio, Is an Independent Prognostic Factor after Resection of Pancreatic Carcinoma. <i>Journal of the American College of Surgeons</i> , 2010, 211, 196-204.	0.5	140
4	Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer. <i>British Journal of Cancer</i> , 2016, 115, 59-65.	6.4	133
5	Sarcopenia is closely associated with pancreatic exocrine insufficiency in patients with pancreatic disease. <i>Pancreatology</i> , 2017, 17, 70-75.	1.1	72
6	Elevated perioperative serum CA 19-9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma. <i>Journal of Surgical Oncology</i> , 2014, 110, 422-429.	1.7	54
7	Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic carcinoma after surgical resection. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 419-429.	2.3	50
8	Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 37-47.	2.3	49
9	Remnant pancreatic parenchymal volume predicts postoperative pancreatic exocrine insufficiency after pancreatectomy. <i>Surgery</i> , 2016, 159, 885-892.	1.9	41
10	Human Equilibrative Nucleoside Transporter 1 Expression Predicts Survival of Advanced Cholangiocarcinoma Patients Treated With Gemcitabine-Based Adjuvant Chemotherapy After Surgical Resection. <i>Annals of Surgery</i> , 2012, 256, 288-296.	4.2	39
11	A Multicenter, Randomized, Controlled Trial Comparing Reinforced Staplers with Bare Staplers During Distal Pancreatectomy (HiSCO-07 Trial). <i>Annals of Surgical Oncology</i> , 2019, 26, 1519-1527.	1.5	39
12	Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma. <i>Journal of Surgical Oncology</i> , 2012, 106, 174-180.	1.7	35
13	Prognostic Impact of Para-Aortic Lymph Node Micrometastasis in Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 2019-2027.	1.5	33
14	Combined Analysis of Dihydropyrimidine Dehydrogenase and Human Equilibrative Nucleoside Transporter 1 Expression Predicts Survival of Pancreatic Carcinoma Patients Treated with Adjuvant Gemcitabine Plus S-1 Chemotherapy after Surgical Resection. <i>Annals of Surgical Oncology</i> , 2012, 19, 646-655.	1.5	30
15	Reinforced staplers for distal pancreatectomy. <i>Langenbeck's Archives of Surgery</i> , 2017, 402, 1197-1204.	1.9	25
16	Evaluation of the efficacy of daikenchuto (TJ -100) for the prevention of paralytic ileus after pancreaticoduodenectomy: A multicenter, double-blind, randomized, placebo-controlled trial. <i>Surgery</i> , 2016, 159, 1333-1341.	1.9	23
17	Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma. <i>Pancreatology</i> , 2017, 17, 95-102.	1.1	23
18	A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 775-781.	2.3	22

#	ARTICLE	IF	CITATIONS
19	Survival effects of adjuvant gemcitabine plus S-1 chemotherapy on pancreatic carcinoma stratified by preoperative resectability status. <i>Journal of Surgical Oncology</i> , 2016, 113, 405-412.	1.7	18
20	Indicators for proper management of surgical drains following pancreaticoduodenectomy. <i>Journal of Surgical Oncology</i> , 2014, 109, 702-707.	1.7	17
21	A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact. <i>European Journal of Cancer</i> , 2021, 159, 215-223.	2.8	17
22	Prognostic impact of dihydropyrimidine dehydrogenase expression on pancreatic adenocarcinoma patients treated with S-1-based adjuvant chemotherapy after surgical resection. <i>Journal of Surgical Oncology</i> , 2011, 104, 146-154.	1.7	15
23	Clinical Implications of Pre- and Postoperative Circulating Tumor DNA in Patients with Resected Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 3135-3144.	1.5	15
24	Prognostic impact of normalization of serum tumor markers following neoadjuvant chemotherapy in patients with borderline resectable pancreatic carcinoma with arterial contact. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 801-811.	2.3	14
25	Prognostic Significance of Lymph Node Metastasis and Micrometastasis Along the Left Side of Superior Mesenteric Artery in Pancreatic Head Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 2100-2109.	1.7	12
26	Cytoplasmic Hu-Antigen R (HuR) Expression is Associated with Poor Survival in Patients with Surgically Resected Cholangiocarcinoma Treated with Adjuvant Gemcitabine-Based Chemotherapy. <i>Annals of Surgical Oncology</i> , 2018, 25, 1202-1210.	1.5	10
27	Prognostic impact of postoperative complication after pancreatoduodenectomy for pancreatic adenocarcinoma stratified by the resectability status. <i>Journal of Surgical Oncology</i> , 2018, 118, 1105-1114.	1.7	9
28	Nerve Growth Factor Expression Is Not Associated with Perineural Invasion in Extrahepatic Cholangiocarcinoma. <i>Digestive Diseases and Sciences</i> , 2016, 61, 774-784.	2.3	8
29	The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine in combination with S-1 or adjuvant gemcitabine alone. <i>Pancreatology</i> , 2018, 18, 191-197.	1.1	8
30	Clinical characteristics of initial recurrence in lung after surgical resection for pancreatic ductal adenocarcinoma. <i>Pancreatology</i> , 2020, 20, 1472-1478.	1.1	8
31	Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma. <i>Pancreatology</i> , 2021, 21, 564-572.	1.1	8
32	Flooring the Major Vessels with Falciform Ligament to Prevent Post-Pancreatectomy Hemorrhage. <i>World Journal of Surgery</i> , 2020, 44, 3478-3485.	1.6	7
33	An Increased Number of Perineural Invasions Is Independently Associated With Poor Survival of Patients With Resectable Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2015, 44, 1345-1351.	1.1	6
34	Superior Mesenteric Artery Plexus-Preserving Pancreatoduodenectomy with Circumferential Dissection of Lymph Nodes. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1712-1719.	1.7	6
35	Neoadjuvant therapy contributes to nodal downstaging of pancreatic cancer. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 623-632.	1.9	6
36	Operative indication for serous cystic neoplasm of the pancreas. <i>Suizo</i> , 2015, 30, 585-591.	0.1	6

#	ARTICLE	IF	CITATIONS
37	Ruptured left colic arterial aneurysm treated by transcatheter arterial embolization alone and without a subsequent laparotomy: Report of a case. <i>Surgery Today</i> , 2011, 41, 707-712.	1.5	5
38	Impact of Secreted Protein Acidic and Rich in Cysteine (SPARC) Expression on Prognosis After Surgical Resection for Biliary Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 990-999.	1.7	5
39	Reappraisal of the validity of surgery for patients with pancreatic cancer aged 80 years or older stratified by resectability status. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2020, 27, 64-74.	2.6	5
40	Prognostic Value of Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma Stratified by the Resectability Status. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2871-2880.	1.7	5
41	Hepatobiliary and Pancreatic: Long-term survival of serous cystadenocarcinoma of the pancreas with synchronous liver metastases after aggressive surgical resection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 287-287.	2.8	4
42	Usefulness of Amplatzer Vascular Plug for Preoperative Embolization Before Distal Pancreatectomy with En Bloc Celiac Axis Resection. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1352-1357.	2.0	4
43	Validating the Japanese version of the Gastrointestinal Quality of Life Index (GIQLI) questionnaire. <i>Annals of Gastroenterological Surgery</i> , 2020, 4, 597-601.	2.4	4
44	Preoperative risk factors for para-aortic lymph node positivity in pancreatic cancer. <i>Pancreatology</i> , 2021, 21, 606-612.	1.1	4
45	Is surgery justified for elderly patients with extrahepatic cholangiocarcinoma? Reappraisal from a viewpoint of comorbidity and organ function. <i>Surgery Today</i> , 2021, 51, 1787-1794.	1.5	4
46	Optimal lymph-node dissection for pancreatic tail cancer. <i>Surgery Today</i> , 2022, 52, 1307-1312.	1.5	4
47	Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: Dosing considerations. <i>Pancreatology</i> , 2014, 14, 95-99.	1.1	3
48	Prognostic significance of dissecting the nerve plexus around the common hepatic artery in pancreatic cancer. <i>Langenbeck's Archives of Surgery</i> , 2021, 406, 679-689.	1.9	3
49	Preservation of pancreatic endocrine and exocrine function of patients who underwent pancreatic resection. <i>Suizo</i> , 2017, 32, 706-713.	0.1	3
50	Identification of Preoperative Risk Factors for Poor Survival in Patients with Resectable Pancreatic Cancer Treated with Upfront Surgery. <i>Digestive Surgery</i> , 2021, 38, 352-360.	1.2	3
51	Long-term survival after distal pancreatectomy with celiac axis resection and hepatic artery reconstruction in the setting of locally advanced unresectable pancreatic cancer. <i>Clinical Journal of Gastroenterology</i> , 2022, 15, 635-641.	0.8	3
52	Preoperative risk factors for positivity of peritoneal lavage cytology in patients with pancreatic ductal adenocarcinoma in the era of neoadjuvant therapy. <i>Pancreatology</i> , 2022, 22, 583-589.	1.1	3
53	Prognosis following an extended duration of adjuvant gemcitabine plus Sâ€ chemotherapy in patients with pancreatic ductal adenocarcinoma: Analysis using inverse probability of treatment weighting. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2022, 29, 911-921.	2.6	2
54	Postpancreatoduodenectomy Hemorrhage Treated by Combined Transcatheter Arterial Embolization and Superior Mesenteric Artery to Iliac Artery Bypass: Report of a Case. <i>International Surgery</i> , 2015, 100, 1084-1088.	0.1	1

#	ARTICLE	IF	CITATIONS
55	Transition of serum cytokines following pancreaticoduodenectomy: A subsidiary study of JAPANâ€™PD. <i>Oncology Letters</i> , 2018, 16, 6847-6853.	1.8	1
56	Neoadjuvant therapy for pancreatic cancer: an intention-to-treat analysis. <i>Langenbeck's Archives of Surgery</i> , 2020, 405, 623-633.	1.9	1
57	The prognostic impact of peritoneal washing cytology for otherwise resectable extrahepatic cholangiocarcinoma patients. <i>Surgery Today</i> , 2021, 51, 1227-1231.	1.5	1
58	A case of mixed adeno-neuroendocrine carcinoma with liver metastasis of neuroendocrine tumor component after adjuvant chemotherapy: a case report and literature review. <i>Suizo</i> , 2017, 32, 752-759.	0.1	1
59	Strategy for the surgical treatment of non-functional pancreatic neuroendocrine tumors. <i>Suizo</i> , 2019, 34, 97-105.	0.1	1
60	Increased clostridium difficile infection in the era of preoperative chemotherapy for pancreatic cancer. <i>Pancreatology</i> , 2022, 22, 258-263.	1.1	1
61	Clinicopathological features of gastric cancer after pancreaticoduodenectomy: reporting of three institutional cases and review of the global literature. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 2259-2271.	1.9	1
62	ASO Author Reflections: Optimal Technical Management of Pancreatic Transection During Distal Pancreatectomy. <i>Annals of Surgical Oncology</i> , 2019, 26, 643-644.	1.5	0
63	<p>No Significant Effect of Daikenchuto (TJ-100) on Peritoneal IL-9 and IFN-Î³ Levels After Pancreaticoduodenectomy</p>. <i>Clinical and Experimental Gastroenterology</i> , 2020, Volume 13, 461-466.	2.3	0
64	New surgical technique for pancreatic lithotripsy without coring-out. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 1343-1346.	0.8	0
65	Reply to the Letter to the Editor â€œRe: A Multicenter, Randomized, Controlled Trial Comparing Reinforced Staplers with Bare Staplers During Distal Pancreatectomy (HiSCO-07 Trial)â€œ. <i>Annals of Surgical Oncology</i> , 2020, 27, 950-951.	1.5	0
66	Immunohistological evaluation of mismatch repair deficiency in pancreatic ductal adenocarcinoma treated with surgical resection. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2020, 27, 421-428.	2.6	0
67	Coexisting Pancreatic Ductal Adenocarcinomas Derived from and Concomitant with Intraductal Papillary Mucinous Neoplasm in a Case with Pancreatic Divisum. <i>Japanese Journal of Gastroenterological Surgery</i> , 2021, 54, 408-415.	0.1	0
68	2r1¼ŽBRè†µç™CEã®è†°ã°Šç—...ç†°† çš,,ç%o1â¾4ã°ã®æ²»ç™,æ^†ç•¥. <i>Suizo</i> , 2018, 33, 18-26.	0.1	0
69	Impact of disintegrin and metalloproteinase domain-containing protein 12 on pancreatic ductal adenocarcinoma treated with surgical resection and perioperative chemotherapy. <i>Pancreatology</i> , 2022, , .	1.1	0